UPDATED 5:00 PM PT – Friday, February 26, 2021
— Meg Tirrell (@megtirrell) February 26, 2021
Eli Lilly is expected to ship the doses out by the end of March. The treatment combines 700 mg of bamlanivimab and 1400 mg of etesevimab. The government will also have the option to buy 1.1 million more doses of the treatment through the end of November.
Today, Lilly announced an agreement with the U.S. government to provide doses of our investigational neutralizing antibodies administered together for the treatment of mild to moderate #COVID19 in high-risk patients. Learn more: https://t.co/V1rfceMyLR pic.twitter.com/DQCobQURhY
— Eli Lilly and Company (@LillyPad) February 26, 2021
In November of 2020, Eli Lilly’s antibody cocktail received Emergency Use Authorization for use in high-risk COVID-19 patients.
While vaccines may prevent #COVID19, monoclonal antibody treatments could improve COVID-19 symptoms in certain people and help them stay out of the hospital. Learn more: https://t.co/Krfz2EYvMU pic.twitter.com/GWf0QQ0X2C
— Eli Lilly and Company (@LillyPad) February 25, 2021